On the stock market since 2016, it operates in the world of health and science. It has 79 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 26% a year on average.
Sales run at $28.6M a year. A small number, but proof the product has real buyers.
A loss of $713K against $28.6M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0050. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, TSSNF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TSSNF is a high-risk stock — not yet profitable, and its future rides on its product catching on.